Key result
Low-dose slow infusion tPA resolves thrombotic coronary occlusions in a stable patient case series.
Why the study?
There is no clinical predictor of coronary artery thrombosis and no consensus regarding the optimal treatment.
Does low-dose slow infusion tissue plasminogen activator (tPA) improve outcomes in hemodynamically stable patients with thrombotic coronary artery occlusions?
Case Report
Does low-dose slow infusion tissue plasminogen activator (tPA) improve outcomes in hemodynamically stable patients with thrombotic coronary artery occlusions?
Low-dose slow infusion tPA may offer a viable reperfusion strategy for hemodynamically stable patients with thrombotic coronary artery occlusions.
Thrombotic coronary artery occlusions usually manifest as acute coronary syndrome with cardiogenic shock, acute pulmonary edema, cardiac arrest, fatal arrhythmias, or sudden cardiac death. Although it usually occurs based on atherosclerosis, it can also occur without atherosclerosis. There is no predictor of coronary artery thrombosis clinically and no consensus regarding the optimal treatment. In the current literature, treatment options include emergency coronary artery bypass grafting, entrapment of thrombus in vessel wall with stent implantation, intracoronary thrombolysis, glycoprotein IIb/IIIa inhibitors, anticoagulation with heparin, and thrombus aspiration as reperfusion strategies. Here, we reviewed a new treatment strategy based on the literature, and a case series with successful results in hemodynamically stable patients with low-dose slow infusion tissue plasminogen activator (tPA) for thrombotic coronary artery occlusions that allow coronary flow was reported. Prospective randomized studies and common consensus are needed on low-dose, slow-infusion tissue plasminogen activator treatment regimen and optimal treatment management for thrombotic coronary artery occlusions.
No takes yet. Share an insight, caveat, or question.
Akçay et al. (2022) conducted a case report in Thrombotic coronary artery occlusions. Low-dose slow infusion tissue plasminogen activator (tPA) was evaluated. Low-dose slow infusion tissue plasminogen activator (tPA) yielded successful results in a case series of hemodynamically stable patients with thrombotic coronary artery occlusions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: